KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Operating Expenses (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Operating Expenses for 16 consecutive years, with $544.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 344.59% to $544.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $927.6 million, a 99.98% increase, with the full-year FY2025 number at $927.6 million, up 99.98% from a year prior.
  • Operating Expenses was $544.7 million for Q4 2025 at Halozyme Therapeutics, up from $136.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $544.7 million in Q4 2025 to a low of $38.3 million in Q1 2021.
  • A 5-year average of $122.2 million and a median of $120.4 million in 2022 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: fell 9.85% in 2024, then surged 344.59% in 2025.
  • Halozyme Therapeutics' Operating Expenses stood at $45.5 million in 2021, then skyrocketed by 135.3% to $107.0 million in 2022, then increased by 20.58% to $129.0 million in 2023, then decreased by 5.04% to $122.5 million in 2024, then surged by 344.59% to $544.7 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Operating Expenses are $544.7 million (Q4 2025), $136.3 million (Q3 2025), and $123.3 million (Q2 2025).